Is Astrana Health, Inc. (NASDAQ:ASTH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Astrana Health, Inc. at current levels.
A capitated-care roll-up trading like a hospital chain, just as risk-bearing primary care eats traditional fee-for-service from the inside.
Where ASTH is headed
By the back half of 2027, Astrana looks less like a regional California medical group and more like the operating system for risk-bearing physician networks across the Sun Belt. The Prospect Health acquisition closed last year roughly doubled the lives under management, pushing the network past 1.7 million members and stretching the footprint into Texas, Arizona, Rhode Island and Connecticut. Care Enablement, the technology and admin layer they sell to affiliated and third-party groups, becomes the part the market eventually pays a real multiple for, because it carries software-like margins on top of a capitated medical book.
Read the full Compass Direction on ASTH
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $38.29).
See the full ASTH analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Astrana Health, Inc. (NASDAQ:ASTH) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Astrana Health, Inc. at current levels. A capitated-care roll-up trading like a hospital chain, just as risk-bearing primary care eats traditional fee-for-service from the inside.
What is ASTH's Compass Score?
Astrana Health, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ASTH?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ASTH page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.